Tetra Bio-Pharma (DB:JAM1) - Aktienkurs, Nachrichten und Analyse

JAM1 Aktienübersicht

A biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology.

Über das Unternehmen

JAM1 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	0/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Die Erträge sind in den letzten 5 Jahren um 42.8% pro Jahr zurückgegangen

Hat keine nennenswerte Marktkapitalisierung (€13M)

Erzielt weniger als 1 Million USD an Einnahmen (CA$0)

Negatives Eigenkapital

+ 3 mehr Risiken

Tetra Bio-Pharma Inc. Wettbewerber

Biofrontera

XTRA:B8FK

€18.4m

SynBiotic

DUSE:SBX

€36.2m

Redx Pharma

DB:0RX

€65.0m

Apontis Pharma

XTRA:APPH

€69.3m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Tetra Bio-Pharma
Historische Aktienkurse
Aktueller Aktienkurs	CA$0.013
52-Wochen-Hoch	CA$0.065
52-Wochen-Tief	CA$0.0046
Beta	2.26
11 Monat Veränderung	0%
3 Monate Veränderung	-0.79%
1 Jahr Veränderung	-59.28%
33 Jahre Veränderung	-92.13%
5 Jahre Veränderung	-97.16%
Veränderung seit IPO	-72.83%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	JAM1	DE Pharmaceuticals	DE Markt
7D	0%	-3.6%	-0.6%
1Y	-59.3%	-15.6%	2.9%

Rendite im Vergleich zur Industrie: JAM1 unter dem Niveau der Branche German Pharmaceuticals, die im vergangenen Jahr eine Rendite von -20.1% erzielte.

Rendite vs. Markt: JAM1 hinter dem Markt German zurück, der im vergangenen Jahr eine Rendite von 8.6 erzielte.

Preisvolatilität

Is JAM1's price volatile compared to industry and market?
JAM1 volatility
JAM1 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.9%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.7%
10% least volatile stocks in DE Market	2.6%

Stabiler Aktienkurs: JAM1 hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von JAM1 im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
n/a	33	Guy Chamberland	www.tetrabiopharma.com

Tetra Bio-Pharma Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Tetra Bio-Pharma im Vergleich zum Marktanteil des Unternehmens?
JAM1 grundlegende Statistiken
Marktanteil	€8.97m
Gewinn(TTM)	-€27.15m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

-0.3x

Kurs-Gewinn-Verhältnis

Ist JAM1 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
JAM1 Gewinn- und Verlustrechnung (TTM)
Einnahmen	CA$0
Kosten der Einnahmen	CA$0
Bruttogewinn	CA$0
Sonstige Ausgaben	CA$39.02m
Umsatz	-CA$39.02m

Zuletzt gemeldete Gewinne

Aug 31, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.076
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	-28.1%

Wie hat sich JAM1 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

JAM1 Aktienübersicht

Belohnungen

Risikoanalyse

Tetra Bio-Pharma Inc. Wettbewerber

XTRA:B8FK

€18.4m

DUSE:SBX

€36.2m

DB:0RX

€65.0m

XTRA:APPH

€69.3m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Tetra Bio-Pharma Inc. Provides Its Shareholders with Another Regulatory Update on the REDUVO™ New Drug Submission

Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir

Tetra Bio-Pharma Inc. Provides Update on Its REDUVO™ New Drug Submission

Tetra Bio-Pharma Inc. and Prepaire Jointly Apply to BARDA for Funding

Tetra Bio-Pharma Inc. announced that it expects to receive CAD 6 million in funding from Alpha Blue Ocean Advisors Ltd

Tetra Bio-Pharma Inc. Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections

Recent updates

Tetra Bio-Pharma Inc. Provides Its Shareholders with Another Regulatory Update on the REDUVO™ New Drug Submission

Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir

Tetra Bio-Pharma Inc. Provides Update on Its REDUVO™ New Drug Submission

Tetra Bio-Pharma Inc. and Prepaire Jointly Apply to BARDA for Funding

Tetra Bio-Pharma Inc. announced that it expects to receive CAD 6 million in funding from Alpha Blue Ocean Advisors Ltd

Tetra Bio-Pharma Inc. Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections

High number of new and inexperienced directors

Tetra Bio-Pharma Inc. Provides Regulatory Update

Tetra Bio-Pharma Inc. Appoints Leslie Auld as Chief Financial Officer

Tetra Bio-Pharma Receives Ema Orphan Drug Designation for A Novel Topical Therapeutic Containing Cbd

Tetra Bio-Pharma Inc. announced that it expects to receive funding from Cannvalate PTY LTD

High number of new and inexperienced directors

Tetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBD

Tetra Bio-Pharma Inc. has completed a Composite Units Offering in the amount of CAD 2.129432 million.

Tetra Bio-Pharma Inc. Announces Positive Initial Clinical Data from its Ongoing Phase 2 Clinical Trials (REBORN©1 and PLENITUDE©) of QIXLEEF™ for Cancer Pain

Tetra Bio-Pharma Accelerates REBORN1© Trial

Significant Discovery Reveals New Antiviral Properties of Tetra Bio- Pharma's Innovative Drug ARDS-003

Independent Chairman of the Board William Cheliak has left the company

Health Canada Accepts New Drug Submission for REDUVO™ as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting

Independent Director has left the company

Tetra Bio-Pharma Announces Clinical Advancements

Tetra Bio-Pharma Inc. has completed a Composite Units Offering in the amount of CAD 10 million.

Tetra Bio-Pharma Inc. Accelerates Plenitude Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain

Tetra Bio-Pharma Announces Start of the Reborn1(C) Clinical Trial

Tetra Bio-Pharma Inc. Re-Activates Veterinary Clinical Study in Companion Animals

Tetra Bio-Pharma Inc., Annual General Meeting, May 28, 2021

Tetra Bio-Pharma Provides Status of its New Drug Submission Application in Canada

Tetra Bio-Pharma Inc. has completed a Composite Units Offering in the amount of CAD 12.54 million.

Tetra Bio-Pharma Inc. (TSX:TBP) entered into a non-binding term sheet to acquire remaining 80% stake in Targeted Pharmaceuticals, LLC for approximately $9.5 million.

New 90-day high: €0.24

Tetra Bio-Pharma Inc. announced that it has received CAD 1.884461 million in funding

Tetra Bio-Pharma Announces FDA Clearance on IND, Allowing U.S. Reborn Clinical Trial to Commence

Tetra Bio-Pharma Inc. announced that it expects to receive CAD 1.894 million in funding

Tetra Bio-Pharma Inc. Completes Investigational New Drug (Ind) -Enabling Toxicology, Clearing the Way for Human Clinical Trials for Its Novel Drug Candidate Ards-003

Tetra Bio-Pharma Inc. Provides Update on Market Potential of ARDS-003

Mondias Natural Products Inc. (TSXV:NHP) completed the acquisition of Lumiera Health Innovation Inc. from Tetra Bio-Pharma Inc. (TSXV:TBP) and certain minority shareholders.

Tetra Bio-Pharma Inc. Unveils Its Commercial Vision on a Robust Chemotherapy Induced Nausea and Vomiting Portfolio

Tetra Bio-Pharma Inc. Enters into A Definitive Agreement with a USA Strategic Partner to Acquire the Canadian Exclusive Rights for Dronabinol Soft Gel Capsules

Tetra Bio-Pharma Inc.(TSXV:TBP) dropped from S&P/TSX Venture Composite Index

Mondias Natural Products Inc. (TSXV:NHP) signed a binding letter of intent to acquire Lumiera Health Innovation Inc. from Tetra Bio-Pharma Inc. (TSXV:TBP) for CAD 1.4 million.

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Tetra Bio-Pharma Inc.'s Grundlagenzusammenfassung

0.0x

-0.3x

Erträge &amp; Einnahmen

Erträge & Einnahmen